Arjo AB/Skr ARJO B
1D1W1MYTD1Y5YMAX
Capital at risk
About Arjo AB
Arjo AB is a Swedish company operating in the medical technology industry, specializing in products and solutions that improve the quality of life for patients with reduced mobility and age-related health challenges. The company's offerings include medical beds, patient transfer systems, hygiene systems, and pressure injury prevention products. Founded in 1957, Arjo has a long history in healthcare solutions and is headquartered in Malmö, Sweden. The company operates globally, with a significant presence in Europe, North America, and other regions. Arjo's competitive strength lies in its focus on enhancing patient outcomes and caregiver efficiency through innovative and ergonomic healthcare solutions.
- Ticker
- Skr ARJO B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 7,000
- Headquarters
- Malmö, Sweden
- Website
- www.arjo.com
Arjo AB Metrics
BasicAdvanced
kr 7.6B
19.73
kr 1.41
0.68
kr 0.95
3.41%
Price and volume
Market cap
kr 7.6B
Beta
0.68
52-week high
kr 34.42
52-week low
kr 23.64
Average daily volume
246K
Dividend rate
kr 0.95
Financial strength
Current ratio
1.157
Quick ratio
0.8
Long term debt to equity
0.459
Total debt to equity
0.723
Dividend payout ratio (TTM)
67.45%
Interest coverage (TTM)
3.59%
Profitability
EBITDA (TTM)
1,452
Gross margin (TTM)
42.00%
Net profit margin (TTM)
3.52%
Operating margin (TTM)
7.89%
Effective tax rate (TTM)
28.09%
Revenue per employee (TTM)
kr 1,560,000
Management effectiveness
Return on assets (TTM)
3.46%
Return on equity (TTM)
5.02%
Valuation
Price to earnings (TTM)
19.733
Price to revenue (TTM)
0.694
Price to book
0.97
Price to tangible book (TTM)
20.11
Price to free cash flow (TTM)
8.281
Free cash flow yield (TTM)
12.08%
Free cash flow per share (TTM)
3.359
Dividend yield (TTM)
3.41%
Forward dividend yield
3.41%
Growth
Revenue change (TTM)
-3.08%
Earnings per share change (TTM)
-10.70%
3-year revenue growth (CAGR)
1.21%
3-year earnings per share growth (CAGR)
-1.27%
3-year dividend per share growth (CAGR)
3.78%
Bulls say / Bears say
Organic Q2 net sales of SEK 2 759 million grew 4.7% year-over-year and topped the IBES consensus of SEK 2 713 million, while adjusted EBITDA of SEK 482 million and adjusted EBIT of SEK 211 million both beat estimates, demonstrating strong operational execution and demand (Reuters)
Arjo received an initial refund of approximately SEK 22 million related to US tariffs under IEEPA, improving cash flow and offsetting some import duty pressures (Reuters)
Wall Street’s median 12-month price target for Arjo is SEK 30.00, about 12.5% above its mid-July closing price, indicating analyst confidence in further share appreciation (Reuters)
Underlying Q1 profitability matched prior-year levels only when excluding the effects of currencies and US tariffs, underscoring persistent external headwinds on Arjo’s margins (Reuters)
The company did not provide specific guidance for future quarters or the full year following its Q2 report, creating uncertainty around its forward performance outlook (Reuters)
Q1 adjusted EBITDA of SEK 456 million fell slightly short of the IBES consensus of SEK 457.2 million, highlighting challenges in sustaining profitability amid ongoing cost pressures (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Upcoming events
No upcoming events
Funds containing Arjo AB
AllEURGBPUSD
Fund name | Fund size | Skr ARJO B weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.03% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.